A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancerResearch in context

A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancerResearch in context

Background: Locally advanced pancreatic cancer (LAPC) has a dismal prognosis with current treatment modalities and one-third of patients die from local progression of disease. Preclinical studies with orthotopic PC demonstrated dramatic synergy between radiotherapy (RT) and the poly(ADP-ribose) poly...

Full description

Bibliographic Details
Main Authors: R. Tuli, S.L. Shiao, N. Nissen, M. Tighiouart, S. Kim, A. Osipov, M. Bryant, L. Ristow, V.R. Placencio-Hickok, D. Hoffman, S. Rokhsar, K. Scher, S.J. Klempner, P. Noe, M.J. Davis, A. Wachsman, S. Lo, L. Jamil, H. Sandler, S. Piantadosi, A. Hendifar
Format: Article
Language:English
Published: Elsevier 2019-02-01
Series:EBioMedicine
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396418306376

Internet

http://www.sciencedirect.com/science/article/pii/S2352396418306376

Similar Items